The cytotoxic effects of lipidic formulated gold porphyrin nanoparticles for the treatment of neuroblastoma

Nanotechnology, Science and Applications

Volumn 3, Issue 1, 2010, Pages 23-28

  Lee, Puiyan ^a   Zhu, Yifan ^a   Yan, Jessie J ^b   Sun, Raymond W Y ^b   Hao, Wei ^a   Liu, Xuelai ^a   Che, Chi Ming ^b   Wong, Kenneth K Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Gold porphyrin; Lipidic formulation; Nanoparticles; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; GOLD PORPHYRIN; LIPID NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PARTICLE SIZE; SURVIVAL RATE; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY;

EID: 77955524072     PISSN: None     EISSN: 11778903     Source Type: Book Series    
DOI: None     Document Type: Article

References (30)

1. Laverdiere C, Liu, Q, Yasui, Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:1131-1140.
2. Matthay KK, Villablanca, JG, Seeger, RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
3. Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219:177-186.
4. Kim E, Moore J, Huang J, et al. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg. 2001;36:287-290.
5. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Canc Res. 1986;46:6387-6392.
6. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carr Sys. 1989;6: 193-210.
7. Jun YJ, Kim JI, Jun MJ, Sohn YS. Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum (II) conjugates. J Inorg Biochem. 2005;99:1593-1601.
8. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enz Reg. 2001;41:189-207.
9. Tanaka T, Shiramoto S, Miyashita M, et al. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm. 2004;277:39-61.
10. Che CM, Sun R, Yu WY, et al. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun. 2003;14:1718-1719.
11. Sun RWY, Che CM, The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Chem Rev. 2009;253:1682-1691.
12. Shaw IC. Gold-based therapeutic agents. Chem Rev. 1999;99: 2589-2600.
13. To YF, Sun RWY, Chen Y, et al. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo. Int J Cancer. 2009;124:1971-1979.
14. Bindoli A, Rigobello MP, Scutari G, et al. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Chem Rev. 2009;253:1692-1707.
15. Tu S, Sun RWY, Lin MCM, et al. Gold(III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer. Cancer. 2009;115:4459-4469.
16. Wang Y, He QY, Sun RWY, et al. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005;65:11553-11564.
17. Koziara JM, Oh JJ, Akers WS, et al. Blood compatibility of cetyl alcohol/ polysorbate-based nanoparticles. Pharm Res. 2005;22:1821-1828.
18. Akiyama Y, Mori T, Katayama Y, Niidome T. The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice. J Cont Rel. 2009;139:81-84.
19. Hsu CH, Cui Z, Mumper RJ, Jay M. Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. AAPS Pharm Sci Tech. 2003;4:E32.
20. Seymour LW, Duncan R, Strohalm J, et al. Effect of molecular-weight (mbarw) of N-(2 hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mat Res. 1987;21:1341-1358.
21. Nagy JA, Herzberg KT, Masse EM, et al. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res. 1989;49:5448-5458.
22. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
23. Li W, Xie Y, Sun RWY, et al. Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Br J Cancer. 2009;101:342-349.
24. Wu J, Lu Y, Lee A, et al. Reversal of multidrug resistance by transferrinconjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007;10:350-357.
25. Grunze M, Haest CW, Deuticke B. Lateral segregation of membrane lipids and formation of stable rod-shaped membrane projections in erythrocytes treated with long-chain alcohols. Biochem Biophys Acta. 1982;693:237-245.
26. Schmidt ML, Kuzmanoff KL, Ling-Indeck L, et al. Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer. 1997;33:2007-2010.
27. Auf G, Chen L, Fornès P, et al. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Let. 2002;327:189-192.
28. Katsanis E, Blazar BR, Bausero MA, et al. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune-response. J Ped Surg. 1994;29:538-542.
29. Li W, Xie Y, Sun RWY, et al. Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition. Brit J Canc. 2009;101:342-349.
30. Bartlett DW, Su H, Hildebrandt IJ, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Nat Acad Sci U S A. 2007;104:15549-15554.